MX2022009825A - Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. - Google Patents

Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.

Info

Publication number
MX2022009825A
MX2022009825A MX2022009825A MX2022009825A MX2022009825A MX 2022009825 A MX2022009825 A MX 2022009825A MX 2022009825 A MX2022009825 A MX 2022009825A MX 2022009825 A MX2022009825 A MX 2022009825A MX 2022009825 A MX2022009825 A MX 2022009825A
Authority
MX
Mexico
Prior art keywords
cell receptors
mutation
restricted
hla class
tcrs
Prior art date
Application number
MX2022009825A
Other languages
English (en)
Spanish (es)
Inventor
Steven A Rosenberg
Maria R Parkhurst
Noam Levin
Iii Frank J Lowery
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2022009825A publication Critical patent/MX2022009825A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
MX2022009825A 2020-02-14 2021-02-12 Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. MX2022009825A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976655P 2020-02-14 2020-02-14
US202063060340P 2020-08-03 2020-08-03
PCT/US2021/017852 WO2021163477A1 (en) 2020-02-14 2021-02-12 Hla class i-restricted t cell receptors against ras with g12v mutation

Publications (1)

Publication Number Publication Date
MX2022009825A true MX2022009825A (es) 2022-10-13

Family

ID=74860482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009825A MX2022009825A (es) 2020-02-14 2021-02-12 Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.

Country Status (12)

Country Link
US (1) US20230082787A1 (https=)
EP (1) EP4103598A1 (https=)
JP (1) JP7735285B2 (https=)
KR (1) KR20220143875A (https=)
CN (1) CN115315441A (https=)
AU (1) AU2021220957A1 (https=)
BR (1) BR112022015897A2 (https=)
CA (1) CA3167382A1 (https=)
GB (1) GB2610311B (https=)
MX (1) MX2022009825A (https=)
TW (1) TWI902755B (https=)
WO (1) WO2021163477A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
WO2023232785A1 (en) * 2022-05-30 2023-12-07 Hs Diagnomics Gmbh Common tumor-specific t cell receptors
CN118852452A (zh) * 2023-04-28 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
MX384919B (es) 2014-11-26 2025-03-14 Us Health Receptores de células t de kras anti-mutado.
JP7185524B2 (ja) * 2015-09-15 2022-12-07 アメリカ合衆国 Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
US20170319638A1 (en) * 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer
EP3684799A1 (en) 2017-09-20 2020-07-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hla class ii restricted t cell receptors against mutated ras
EP3720478A1 (en) * 2017-12-04 2020-10-14 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against mutated ras
EP3731861A1 (en) * 2017-12-29 2020-11-04 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof

Also Published As

Publication number Publication date
TW202140535A (zh) 2021-11-01
JP2023526149A (ja) 2023-06-21
GB2610311A (en) 2023-03-01
KR20220143875A (ko) 2022-10-25
CN115315441A (zh) 2022-11-08
EP4103598A1 (en) 2022-12-21
US20230082787A1 (en) 2023-03-16
JP7735285B2 (ja) 2025-09-08
TWI902755B (zh) 2025-11-01
GB202211757D0 (en) 2022-09-28
WO2021163477A8 (en) 2022-09-29
GB2610311B (en) 2025-07-09
CA3167382A1 (en) 2021-08-19
AU2021220957A1 (en) 2022-09-01
BR112022015897A2 (pt) 2022-10-18
WO2021163477A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
MX2022009825A (es) Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
MX2022009654A (es) Receptor de células t restringido por hla de la clase i contra ras con mutación g12d.
MX2022010157A (es) Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
MX2024005678A (es) Receptores de celulas t que reconocen p53 mutado.
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
AU2024202903A1 (en) Neoantigen identification, manufacture, and use
Lam et al. An empirical antigen selection method identifies neoantigens that either elicit broad antitumor T-cell responses or drive tumor growth
BR112021026408A2 (pt) Receptores de célula t que reconhecem a mutação r175h ou y220c em p53
AU2025279629A1 (en) Neoantigen identification for T-cell therapy
CN113711239A (zh) 利用ii类mhc模型鉴别新抗原
CN119851752A (zh) 利用泛等位基因模型进行的新抗原鉴别
AU2018348165A1 (en) Neoantigen identification using hotspots
CA3066635A1 (en) Neoantigen identification, manufacture, and use
WO2019036043A2 (en) METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
US20230197192A1 (en) Selecting neoantigens for personalized cancer vaccine
WO2022015694A8 (en) Hla class ii–restricted drb t cell receptors against ras with g12d mutation
Yao et al. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer
WO2024206274A3 (en) T cell receptors targeting y220c or r175h mutation in p53
CN110464840A (zh) 一种肿瘤疫苗的制备方法及使用该方法制备的肿瘤疫苗
CN116287158A (zh) 一种新抗原鉴定和疗效预测方法
WO2021262829A3 (en) Hla class i-restricted t cell receptors against cd20
WO2022051449A3 (en) T cell receptors recognizing r273c or y220c mutations in p53
KR102182555B1 (ko) T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼
WO2026024602A3 (en) T cell receptors against ras with g12d, g12v, g13d or q61r mutation